BMS × Hengrui Pharma Enter Strategic Partnership Worth Up to $15.2 Billion
Bristol Myers Squibb and Hengrui Pharma have announced a global strategic collaboration and licensing agreement worth up to $15.2 billion.
The collaboration covers 13 early-stage programmes across oncology, hematology, and immunology. Rather than a single asset licensing deal, this partnership combines multiple candidates and newly discovered programmes within a broader co-development framework.
Partnership highlights
- 13 early-stage programmes in total
- 4 oncology and hematology candidates from Hengrui Pharma
- 4 immunology candidates from BMS
- 5 new candidates to be jointly discovered and developed
- $600 million upfront, with near-term payments bringing the initial consideration to up to $950 million
- Total potential deal value of up to $15.2 billion, including milestone payments
Under the agreement, BMS will receive rights to four Hengrui-originated candidates outside mainland China, Hong Kong, and Macau. Hengrui Pharma will receive rights to four BMS-originated candidates in those territories.
One of the most notable aspects of this partnership is that Hengrui Pharma will lead early clinical development in China, while BMS will use the resulting data to inform global development decisions. This suggests that Chinese pharmaceutical companies are playing a deeper role in early global development processes, beyond the traditional out-licensing of later-stage assets.
As drug discovery and clinical development become increasingly cross-regional, the ability to connect early clinical execution, development strategy, regulatory planning, and business development is becoming more important. As a talent solutions partner specialised in life sciences, Greenstaff Life Sciences will continue to follow developments in global drug discovery and clinical development models.